

1 **Partial Mootness**

2 The Court is obligated to address jurisdictional issues even if the parties do not raise
3 them. *See Mt. Healthy City School Dist. Bd. of Ed. v. Doyle*, 429 U.S. 274, 278 (1977). At
4 a hearing in the related case, 16cv2762, *Profil Institut für Stoffwechselforschung GmbH v.*
5 *Prosciento, Inc.*, the Court held a hearing on Profil's motion for a preliminary injunction
6 involving alleged trademark infringement in the EU. At that hearing, Defendant's counsel
7 announced that the company was changing its name to ProSciento. The Court accepted this
8 representation and concluded that, going forward, ProSciento would be unlikely to use the
9 "Profil" trademark in the EU and would be abandoning further use of the trademark. In light
10 of this, the Court ordered the parties to show cause why claims for injunctive relief
11 concerning use of the trademark were not moot. (Docket no. 32.)

12 Before either party filed briefing, ProSciento filed a motion for a preliminary injunction,
13 claiming that it owns the trademark and asking the Court to enjoin Profil from using it. The
14 Court denied the motion without prejudice, noting that ProSciento had no counterclaim
15 pending, and that mootness had not yet been addressed. The parties filed responses to the
16 Court's order to show cause, saying that ownership of the mark is still being actively disputed
17 and that ProSciento intends to keep using it in the U.S. This change in position causes
18 concern; a party should not benefit from contradictory factual assertions. But the
19 circumstances do not suggest an intent to mislead the Court. The Court accepts that the
20 parties both intend to use the mark in the United States, and its ownership is actively
21 contested. The order to show cause is therefore **DISCHARGED**.

22 **Motion to Dismiss**

23 ProSciento filed a motion under Fed. R. Civ. P. 12(b)(6) (Docket no. 17) to dismiss the
24 amended complaint (the "FAC"). Three agreements which were mentioned in the amended
25 complaint are attached as exhibits were attached to the motion. (Docket no. 17-2.) Profil
26 does not dispute these documents' authenticity or object to the Court's considering them in
27 connection with the motion; in fact, its own briefing refers to these documents and relies on
28 them.

1 **Judicial Notice**

2 The motion was accompanied by requests for judicial notice under Fed. R. Evid. 201.
3 Most of the documents (Exhibits A through I) are journal articles. Profil objects to the Court's
4 taking notice of those, and points out they are not authenticated. Profil does not object to the
5 Court's taking notice of Exhibits J or K, which are records from the U.S. Patent and
6 Trademark Office (USPTO).

7 The journal articles are offered to show that certain alleged trade secrets are not in
8 fact secret, and that the information has been made public through articles like these.
9 "Courts may take judicial notice of publications introduced to indicate what was in the public
10 realm at the time" *Von Saher v. Norton Simon Museum of Art at Pasadena*, 592 F.3d
11 954, 960 (9th Cir. 2010). Profil is correct that these articles have not been authenticated.
12 *See Madeja v. Olympic Packers, LLC*, 310 F.3d 628, 639 (9th Cir. 2002) (district court was
13 not required to take notice of unauthenticated documents). Profil also argues that while the
14 articles cover generally the same subject matter as the trade secrets, the trade secrets
15 include information not in the articles. Assuming this is true, the articles would not be helpful
16 at this stage of litigation. The request for judicial notice of Exhibits A through I is therefore
17 **DENIED**. But Exhibits J and K meet the standards for notice under Fed. R. Evid. 201, and
18 the unobjected-to request for judicial notice of those exhibits is **GRANTED**.

19 **Legal Standards for Motion to Dismiss**

20 A Rule 12(b)(6) motion to dismiss tests the sufficiency of the complaint. *Navarro v.*
21 *Block*, 250 F.3d 729, 732 (9th Cir. 2001). Under Fed. R. Civ. P. 8(a)(2), only "a short and
22 plain statement of the claim showing that the pleader is entitled to relief," is required, in order
23 to "give the defendant fair notice of what the . . . claim is and the grounds upon which it
24 rests." *Bell Atlantic Corp. v. Twombly*, 550 U.S. 544, 554-55 (2007). The well-pleaded facts
25 must do more than permit the Court to infer "the mere possibility of conduct"; they must show
26 that the pleader is entitled to relief. *Ashcroft v. Iqbal*, 556 U.S. 662, 679 (2009).

27 When determining whether a complaint states a claim, the Court accepts all
28 allegations of material fact in the complaint as true and construes them in the light most

1 favorable to the non-moving party. *Cedars-Sinai Medical Center v. National League of*
2 *Postmasters of U.S.*, 497 F.3d 972, 975 (9th Cir. 2007) (citation omitted). At the pleading
3 stage, the Court may consider not only the complaint itself, but also documents it refers to,
4 whose authenticity is not questioned, and matters judicially noticed. *Zucco Partners LLC v.*
5 *Digimarc Corp.*, 552 F.3d 981, 990 (9th Cir. 2009).

6 ProSciento raises the statute of limitations as a defense. A claim may be dismissed
7 as untimely on a Rule 12(b)(6) motion only when the running of the statute of limitations is
8 apparent on the face of the complaint. *United States ex rel. Air Control Techs., Inc. v. Pre*
9 *Con Indus., Inc.*, 720 F.3d 1174, 1178 (9th Cir. 2013).

10 If a motion to dismiss is granted, leave to amend is ordinarily granted unless
11 amendment would be futile. *Lopez v. Smith*, 203 F.3d 1122, 1130-31 (9th Cir.2000) (en
12 banc).

13 **Factual Background**

14 Profil, a German entity, was ProSciento's parent corporation. The two companies are
15 in the business of medical research. In 2003, Profil created ProSciento (then Profil Institute
16 for Clinical Research) as a subsidiary. In 2008, the companies formally separated, but
17 worked together under a Cooperation Agreement that terminated in 2012. The Cooperation
18 Agreement is attached to ProSciento's motion to dismiss as Exhibit A. One of the
19 agreement's provisions was that the companies' work would be coordinated, and that they
20 would each use a similar logo that incorporated the word "Profil". Profil alleges it owned the
21 "Profil" mark at this time, and was granting ProSciento a license to use it.

22 In 2009, ProSciento filed an application to register the "Profil" mark in the United
23 States. Also in 2009, the two companies entered into a Lease Agreement for devices known
24 as Biostators. The Lease Agreement is attached to the motion to dismiss as Exhibit B. Profil
25 says it developed and owned trade secrets regarding use of Biostators and related
26 technology and procedures, and that both the Cooperation Agreement and the Lease
27 Agreement included provisions intended to protect trade secrets. (FAC, ¶ 26.)

28 ///

1 After the Cooperation Agreement terminated, the parties entered into a
2 Non-Disclosure Agreement ("NDA"). The NDA is attached as Exhibit C to the motion to
3 dismiss. It included a provision concerning the protection of Profil's interest in trademarks and
4 trade secrets.

5 Profil alleges that ProSciento fraudulently registered the "Profil" mark with the USPTO
6 by falsely claiming it had used the mark first, when in fact Profil had. Profil alleges
7 ProSciento falsely claimed its first use of the mark occurred on December 31, 1999, before
8 ProSciento was even formed. Profil alleges other false statements regarding the first use of
9 that mark. (FAC, ¶¶ 46-52.) ProSciento did not tell Profil it was attempting to register the
10 mark, and Profil first discovered the registration attempt "in or about 2010". (*Id.* ¶¶ 5, 53.)
11 The registration was issued on May 17, 2011.

12 The two companies' relationship soured, and beginning May 18, 2016, ProSciento
13 made it clear it intended to compete with Profil. (FAC, ¶¶ 5-6.) Profile filed this action on
14 June 20, 2016, bringing the following claims:

15 Claim 1, for a declaration that Profil is the mark's prior user and owner;

16 Claim 2, for cancellation of the mark as invalid based on Profil's first use and
17 ownership;

18 Claim 3, for cancellation of the mark for fraud in its procurement;

19 Claim 4, for cancellation of the mark for misuse;

20 Claim 5, for trademark infringement and unfair competition under California
21 law;

22 Claim 6, for trade secret misappropriation under federal law; and

23 Claim 7, for trade secret misappropriation under California law.

24 ProSciento's motion seeks dismissal of claims 2, 3, 6, and 7 with prejudice.

25 **Discussion**

26 To a great extent, the standard for ruling on motions to dismiss controls the outcome
27 of this motion. Much of what ProSciento's motion asks the Court to do is inappropriate at the
28 pleading stage.

///

1 **Incontestability**

2 ProSciento argues Claims 2 and 3 are barred because the trademark is now
3 incontestable under 15 U.S.C. § 1065. Profil does not dispute that the mark has achieved
4 incontestability, but argues that exceptions apply.

5 With regard to Claim 2, Profil argues that incontestability is not valid against the senior
6 user of the mark. Although there is some inconsistency in decisional law, the law of this
7 Circuit favors Profil's position. See *Kabushiki Kaisha Megahouse v. Anjar Co. LLC*, 2014 WL
8 5456523 at *5 (C.D. Cal., Oct. 20, 2014) (discussing conflicting authority).

9 The Ninth Circuit has explained that "the label of 'incontestability' is rather
10 misdescriptive," and that "[a]n incontestable registration is still subject to certain defenses
11 or defects, set forth in 15 U.S.C. § 1115" *KP Permanent Make-Up, Inc. v. Lasting*
12 *Impression I, Inc.*, 408 F.3d 596, 603 (9th Cir. 2005). Among the defects that provide an
13 exception are claims "[t]hat the registration or the incontestable right to use the mark was
14 obtained fraudulently" § 1115(b)(1). Because fraud in registration or procurement of
15 incontestability is an exception to incontestability, Claim 3 is not barred.

16 **Statute of Limitations**

17 ProSciento also argues that Claims 6 and 7 are time-barred, because both the federal
18 and state limitations periods for trade secrets misappropriations claims are three years and
19 the alleged misappropriation began four years ago. It cites *Intermedics, Inc. v. Ventritex,*
20 *Inc.*, 822 F. Supp. 634, 653 (N.D. Cal. 1993) and *MedioStream, Inc. v. Microsoft Corp.*, 869
21 F. Supp. 2d 1095, 1110 (N.D. Cal. 2012), arguing that the claim accrues as of the first
22 misappropriation. The limitations period runs from the time alleged misappropriation is
23 actually discovered, or with the exercise of reasonable diligence should have been
24 discovered, and a continuing misappropriation constitutes a single claim. Cal. Civ. Code §
25 3426.6; 18 U.S.C. §1836(d).

26 Although the Cooperation Agreement allowed ProSciento to use the alleged trade
27 secrets, it continued to use them continuously after the agreement was terminated, around
28 April 4, 2012. If its use amounted to misappropriation, ProSciento argues that the claim

1 accrued shortly after the Cooperation Agreement was terminated, and Profil had three years
2 from that time to bring suit. ProSciento maintains that the FAC fails to allege facts that would
3 suggest Profil was unable to discover the misappropriation, and therefore has not pled facts
4 suggesting it is entitled to tolling.

5 Statutes of limitations are an affirmative defense, Fed. R. Civ. P. 8(c), and a plaintiff
6 is not required to plead facts in anticipation of it. *Unique Functional Products, Inc. v. JCA*
7 *Corp.*, 2012 WL 1416201, at *2 (S.D. Cal., Apr. 23, 2012).

8 ProSciento asks the Court to conclude that Profil was failed in its obligation to
9 investigate reasonable suspicions of misappropriation. (Docket no. 17-1 at 19:11-21.) The
10 FAC does not, however, make plain that "even the most cursory investigation" (id. at 19:16)
11 would have revealed misuse of the Biostators. Nor can the Court conclude that because the
12 Cooperation Agreement had terminated, the parties' cooperative relationship had ended, as
13 ProSciento argues. For example, after it was terminated, the parties entered into the NDA
14 in order to protect trade secrets. A reasonable inference from that might be that the parties
15 were maintaining some kind of cooperative relationship. Another reasonable inference is that
16 ProSciento did not give Profil any reason to suspect it was doing anything improper.

17 In addition, Profil has attached two June 20, 2016 demand letter to the FAC. (Docket
18 no. 5, Exs. A and B.) This letter demands the return of all proprietary information, and
19 identifies the Biostator machines as well as various documents and information. Accepting
20 these letters at face value, it would appear Profil had consented, or thought it may have
21 consented, to ProSciento's retaining the trade secrets, and had come to realize they were
22 being misappropriated. In other words, ProSciento's retention of the Biostator machines,
23 documents, and information did not give Profil any reason for concern for some time after the
24 Cooperation Agreement was terminated. The fact that the parties had entered in to the NDA
25 further supports this inference.

26 The reasoning ProSciento asks the Court to engage in might be acceptable at trial.
27 But the FAC simply does not provide the level of factual information that would make this
28 clear as a matter of law. ProSciento's characterization of the situation could, in the end, turn

1 out to be correct. But when the Court has to draw this many inferences from factual
2 pleadings and supply additional facts, the running of the limitations period cannot be said to
3 appear on the face of the complaint.

4 **Pleading Standards: Fraud**

5 ProSciento cites the heightened pleading standard for fraud under Fed. R. Civ. P.
6 9(b), and argues that Claim 3, for cancellation based on fraud, is inadequately pled.

7 The Ninth Circuit has explained that "[a]ny false statements made in an incontestability
8 affidavit may jeopardize not only the incontestability claim, but also the underlying
9 registration." *Robi v. Five Platters, Inc.*, 918 F.2d 1439, 1444 (9th Cir. 1990). Various false
10 statements will suffice to show fraud. See *id.* (citing examples). See also *Halo Mgt., LLC*
11 *v. Interland, Inc.*, 308 F. Supp. 2d 1019 (N.D. Cal. 2003) (discussing standards for trademark
12 cancellation based on fraud in registration). The Court accepts as true the allegations that
13 Profil first used the mark in the U.S. in 1999, that ProSciento was created in 2003, that in
14 2008 Profil and ProSciento formally separated, and that at the time of the application Profil
15 was using the mark in U.S. commerce. (FAC, ¶¶ 1, 21, 30, 33.) This would make several
16 of ProSciento's statements in the 2009 application and affidavit false, most significantly the
17 representations that ProSciento was the mark's senior user, that ProSciento first used the
18 mark in 1999, and that no one else had the right to use the mark. (FAC ¶¶ 46-49.)

19 Much of ProSciento's argument depends on its status as a subsidiary of Profil. But
20 in 2009 when it submitted the materials, the two companies had already separated and
21 ProSciento was no longer Profil's subsidiary. ProSciento cites no authority to support its
22 contention that former subsidiaries are treated the same as current ones for purposes of
23 trademark registration. It cites the Trademark Man. of Exam. Proc. § 903.05 (5th ed. 2007)
24 for the proposition that use by a related company can be the "first use" date (Docket no. 17-1
25 at 23:27), but this section does not stand for that proposition. The intended citation may
26 have been § 1201.03, but even under that section, it does not appear that ProSciento was
27 a related company at the time it submitted the application.

28 The FAC alleges sufficient facts to plausibly suggest ProSciento knew these facts

1 were false, that they were material, and that the USPTO relied on them. The facts given in
2 the FAC are specific enough to put ProSciento on notice of the particular fraudulent conduct
3 it is charged with, *i.e.*, "the who, what, when, where, and how of the misconduct charged."
4 *See Kearns v. Ford Motor Co.*, 567 F.3d 1120, 1124 (9th Cir. 2009).

5 **Trade Secrets: Pleading Standards**

6 The Court is exercising supplemental jurisdiction over Profil's state law claims (FAC,
7 ¶ 10), and therefore applies state substantive law but federal procedural law. *Cortez v. Skol*,
8 776 F.3d 1046, 1054 n. 8 (9th Cir. 2015). Although the parties have cited and relied on state
9 pleading standards, pleading standards are procedural, and the Court therefore applies
10 federal rather than state pleading standards. *See Hatton v. Bank of America, N.A.*, 2015 WL
11 6739137, at *3 (E.D. Cal., Nov. 2, 2015) (citing *Vess v. Ciba-Geigy Corp. USA*, 317 F.3d
12 1097, 1103 (9th Cir. 2003)).

13 In federal court, plaintiffs seeking relief for misappropriation of trade secrets must
14 identify what they are, and should describe it with sufficient particularity to separate it from
15 either matters of general knowledge in the trade or of special knowledge of those skilled in
16 the trade. *Imax Corp. v. Cinema Technologies, Inc.*, 152 F.3d 1161, 1164-65 (9th Cir. 1998).
17 While *Imax* applied the standard at the summary judgment stage, the pleading standard at
18 this stage requires only notice and plausibility. This requirement has been applied, in a more
19 relaxed form, at the pleading stage. In *Modus LLC v. Encore Legal Solutions, Inc.*, 2013 WL
20 6628125 at *7-8 (D. Ariz., Dec. 17, 2013), for example, the court found it adequate to allege
21 that its trade secrets consisted of software programs it created or modified and that it used
22 in the provision of its business services.

23 Significantly, Profil was the source of the trade secrets, and should know what they
24 are well enough to be able to plead a claim. This is not a case where discovery is needed,
25 or might be needed, to allege facts identifying the trade secrets.

26 ///

27 ///

28 **Trade Secrets: Discussion**

1 The FAC gives general categories of the things Profil considered to be trade secrets.
2 (FAC, ¶ 26.) The first demand letter attached to the complaint also asks for those categories
3 things to be returned. (Docket no. 5 at 29-30.) They are:

- 4 • Biostator machines;
- 5 • Standard Operating Procedures and written manuals for the Biostator
6 machines to perform Glucose Clamp Studies;
- 7 • methods and procedures for using the Biostator machines with the
8 appropriate pumps and tubing, and how to perform necessary maintenance
9 of the machines when performing Glucose Clamp Studies;
- 10 • methods and procedures for preparing clinical development plans to
11 perform clinical studies;
- 12 • methods and procedures for performing insulin-sensitivity assessment with
13 Glucose Clamp Studies; methods and procedures in the design,
14 performance, and data analysis of clinical studies;
- 15 • methods and procedures for data management and analysis;
- 16 • database design, computer software, and procedures for implementing a
17 database to manage and recruit volunteers for various clinical studies.

18 *Id.* The second letter repeats this information but also elaborates, explaining that Profil
19 developed the software for the purpose of analyzing results and reporting. (Docket no. 5 at
20 34.) The Cooperation Agreement further identifies the trade secrets. (Docket no. 17-2, Ex.
21 A at 40-41.)

22 Some of these are not adequately differentiated from general knowledge within the
23 trade, or general public knowledge for that matter. For example, the Biostator machines
24 themselves are identified as a trade secret. The machines' existence and general nature is
25 not a secret, however. It may be that Profil is seeking to have the machines themselves
26 returned, or that the machines' design or some aspects of it are trade secrets. But whatever
27 the trade secret is supposed to be is not very clear. On the other hand, Standard Operating
28 Procedures and manuals for operating the Biostator machines seem to be materials Profil
authored. The volunteer database and program codes, and their general functions are
described in the Cooperation Agreement. (Docket no. 17-2, Ex. A at 41.) But the "methods
and procedures" items are never very well identified, nor are the aspects of them that amount

1 to trade secrets adequately differentiated from what is more generally known. Clearly, others
2 in the industry who perform the same or similar functions use methods and procedures as
3 well. Whatever it is that distinguishes the trade secrets from those should be adequately
4 identified. For example, the FAC does not make clear whether Profil created these
5 procedures or modified existing procedures, or whether the procedures are generally known
6 or used within the industry.

7 The Court concludes that the Standard Operating Procedures and written manuals
8 for the Biostator machines to perform Glucose Clamp Studies; and computer software, and
9 procedures for implementing a database to manage and recruit volunteers for various clinical
10 studies are adequately identified. The Biostator machines are adequately identified only if
11 the FAC is seeking return of the machines themselves; otherwise, they are not. The
12 remainder are not adequately identified.

13 Because not all of the trade secrets are adequately identified, it is difficult to say
14 whether Profil took adequate steps to maintain their status as trade secrets. In some cases,
15 it will be clear as a matter of law that the precautions were inadequate. But the FAC and the
16 agreements make clear Profil took some steps, and their briefing points those out. (See FAC
17 ¶ 27; Docket no. 17-2, Ex. A at 42, ¶ 11 and Ex. C at 1, ¶ 4) Whether those steps were
18 reasonable under the circumstances is a question of fact that is appropriately resolved either
19 at the summary judgment stage or trial. See *Learning Curve Toys, Inc. v. PlayWood Toys,*
20 *Inc.*, 342 F.3d 714, 724-25 (7th Cir. 2003) (whether measures taken to protect trade secrets
21 were reasonable is generally a question of fact for the jury, and only in extreme cases can
22 be decided as a matter of law).

23 **Conclusion and Order**


24 The motion to dismiss is **GRANTED IN PART and DENIED IN PART**. The Court finds
25 the FAC adequately identifies only some of the trade secrets. Claims regarding
26 misappropriation of the Standard Operating Procedures and written manuals for the Biostator
27 machines to perform Glucose Clamp Studies; and computer software, and procedures for
28 implementing a database to manage and recruit volunteers for various clinical studies are

1 adequately pled. Assuming Profil is seeking return of the Biostator machines, they are
2 adequately identified as well; but otherwise, that portion of the claim is not adequately pled.
3 The remainder of the trade secrets are not adequately identified, and to the extent the
4 misappropriation claim concerns those trade secrets, it is **DISMISSED WITHOUT**
5 **PREJUDICE**. But because it is very likely Profil can successfully amend, it may do so within
6 **21 calendar days of the date this order is issued.**

7 In all other respects the motion to dismiss is **DENIED**.

8
9 **IT IS SO ORDERED.**

10 DATED: March 31, 2017

11 A handwritten signature in black ink, reading "Larry A. Burns", is written over a horizontal line.

12 **HONORABLE LARRY ALAN BURNS**
13 United States District Judge
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28